Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Aakriti JainDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0000-0002-2159-0455
Isaac HeremansMetabolic Research Group, de Duve Institute and WELBIO, Universite Catholique de Louvain, Brussels, Belgium.ORCID 0000-0001-6339-4367
Gilles RademakerDepartment of Anatomy and Helen Diller Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0170-781X
Tyler C DetomasiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4390-108X
Peter RohwederDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3194-689X
Dashiell AndersonDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Justin ZhangDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.
Grace A HernandezDepartment of Anatomy and Helen Diller Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6494-6194
Suprit GuptaDepartment of Anatomy and Helen Diller Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0006-1436-5125
Teresa von LindeDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0009-0007-4876-659X
Mike LangeDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.
Martina SpacciDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0009-0006-2928-0159
Jiayi LuoDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0009-0000-7740-0254
Y Rose CitronDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.
James A OlzmannDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0000-0001-7751-8316
David W DawsonDepartment of Pathology and Laboratory Medicine and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-0215-5861
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7704-9185
Guido BommerMetabolic Research Group, de Duve Institute and WELBIO, Universite Catholique de Louvain, Brussels, Belgium.ORCID 0000-0001-6898-4884
Rushika M PereraDepartment of Anatomy and Helen Diller Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Roberto ZoncuDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.ORCID 0000-0003-1611-1891
Funding
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALAN D FRANKEL · 2022 to 2026
$35.7M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Molecular Mechanisms of Lipid Droplet BiogenesisR01GM112948 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI OLZMANN, JAMES A · 2015 to 2024
$3.1M
Molecular Mechanisms of Organelle-based Metabolic SignalingR35GM149302 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI Roberto Zoncu · 2023 to 2026
$2.4M
Dissecting new mechanisms of lysosome quality control in health and diseaseR01CA260249 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERERA, RUSHIKA MIRIAM · 2021 to 2025
Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain-containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of undigested hydrophobic peptides, lysosomal membrane damage, and growth inhibition. Thus, LyLAP enables lysosomal degradation of membrane proteins and protects lysosomal integrity in highly endocytic cancer cells.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. · full record | OpenQuestion